Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | PPARA | Q07869 | 2/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | F9 | P00740 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577774 | 1.00 | TP53 (0.62) | TP53CYP3A4PPARAPPARGGAA | |
| SCHEMBL9863137 | 0.89 | PPARA (0.67) | TP53CYP3A4PPARAPPARGGAA | |
| SCHEMBL7801094 | 0.88 | TSHR (0.59) | TP53CYP3A4PPARAPPARGGAA | |
| SCHEMBL7793679 | 0.85 | TSHR (0.64) | TP53CYP3A4PPARAPPARGTSHR | |
| SCHEMBL11828515 | 0.85 | PPARA (0.63) | TP53CYP3A4PPARAPPARGGAA | |
| SCHEMBL8871613 | 0.85 | TP53 (0.58) | TP53CYP3A4PPARAPPARGTSHR | |
| SCHEMBL7801086 | 0.84 | TSHR (0.71) | TP53CYP3A4PPARAPPARGTSHR | |
| SCHEMBL6494581 | 0.84 | GAA (0.66) | PPARAPPARGGAAKDM4EHSD17B10 | |
| SCHEMBL217079 | 0.84 | CYP3A4 (0.56) | TP53CYP3A4GAAKDM4ETSHR | |
| SCHEMBL8279022 | 0.84 | TSHR (0.57) | TP53CYP3A4PPARAPPARGTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4007752-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220289724-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220259154-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2022-08-18 | — | — | US | disclosed |
| EP-4007752-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| WO-2022086892-A1 | INTERLEUKIN 4 (IL4)-INDUCED GENE 1 INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-114302880-A | KIF18A inhibitors | 美国安进公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2021026098-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0900255-A1 | DONOR-SUBSTITUTED OXINDIGO DERIVATIVES AND THEIR USE AS COLOURANTS | Ciba SC Holding AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5880130-A | TREATMENT OF CELL-PROLIFERATION DISEASES | ZENECA LIMITED (GB) | 1999-03-09 | — | — | US | disclosed |
| WO-1999009024-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-02-25 | — | — | WO | disclosed |
| US-5776929-A | GASTRIN INHIBITOR; GASTROINTESTINAL DISORDERS | SHIONOGI & CO., LTD. (JP) | 1998-07-07 | — | — | US | disclosed |
| WO-1997041176-A1 | DONOR-SUBSTITUTED OXINDIGO DERIVATIVES AND THEIR USE AS COLOURANTS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1997-11-06 | — | — | WO | disclosed |
| US-5610144-A | CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS | RHONE-POULENC RORER S.A. (FR) | 1997-03-11 | — | — | US | disclosed |
| EP-0733045-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015952-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-15 | — | — | WO | disclosed |
| US-4083844-A | Phenylazo orthocyano phenylazo or orthocyano phenylazo phenylazo containing dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259154-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | TP53 219/4885CYP3A4 2249/4885PPARA 2790/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | TP53 486/4885CYP3A4 2948/4885PPARA 3575/4885 |
| US-20220289724-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | TP53 693/4885CYP3A4 4425/4885PPARA 2790/4885 |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | TP53 219/4885CYP3A4 2249/4885PPARA 2790/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | TP53 1171/4885CYP3A4 1599/4885PPARA 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.